Loading
Evorpacept is an experimental immune checkpoint modulator from ALX Oncology in phase 3 trials for gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.
Evorpacept (ALX148) is an immune checkpoint modulator developed by ALX Oncology. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05002127 (A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)), in gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and HER2-positive breast cancer. The largest, NCT05002127, plans to enrol 127 participants (actual) with primary completion was scheduled for 2024-05-24 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Evorpacept binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Evorpacept" OR ABSTRACT:"Evorpacept" OR TITLE:"ALX148" OR ABSTRACT:"ALX148" OR TITLE:"Evorpacept ALX148" OR ABSTRACT:"Evorpacept ALX148") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Evorpacept, not a curated reading list.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-positive breast cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.